Diabetic CKD — ESENeph MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Nonsteroidal MRA (finerenone)
KDIGO/ADA endorse nonsteroidal MRAs (e.g., finerenone) in T2D with persistent albuminuria despite ACEI/ARB to reduce CKD/CV events. A: Steroidal MRAs increase hyperkalemia risk; limited CKD outcome data. C/D/E: Not kidney-protective in this context.
Reference: KDIGO (2022): Diabetes Management in Chronic Kidney Disease